- Home
- RLX vs PTGX Comparison
RLX vs PTGX Comparison
Compare RLX & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLX
- PTGX
- Stock Information
- Founded
- RLX 2018
- PTGX 2006
- Country
- RLX China
- PTGX United States
- Employees
- RLX N/A
- PTGX N/A
- Industry
- RLX Medicinal Chemicals and Botanical Products
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- RLX Health Care
- PTGX Health Care
- Exchange
- RLX Nasdaq
- PTGX Nasdaq
- Market Cap
- RLX 3.3B
- PTGX 2.7B
- IPO Year
- RLX 2021
- PTGX 2016
- Fundamental
- Price
- RLX $2.28
- PTGX $36.82
- Analyst Decision
- RLX Strong Buy
- PTGX Strong Buy
- Analyst Count
- RLX 1
- PTGX 8
- Target Price
- RLX $2.76
- PTGX $54.63
- AVG Volume (30 Days)
- RLX 5.4M
- PTGX 660.4K
- Earning Date
- RLX 03-14-2025
- PTGX 02-25-2025
- Dividend Yield
- RLX 0.44%
- PTGX N/A
- EPS Growth
- RLX 607.62
- PTGX N/A
- EPS
- RLX 0.07
- PTGX 2.68
- Revenue
- RLX $307,798,132.00
- PTGX $323,795,000.00
- Revenue This Year
- RLX $116.31
- PTGX $441.08
- Revenue Next Year
- RLX $46.01
- PTGX N/A
- P/E Ratio
- RLX $32.18
- PTGX $13.72
- Revenue Growth
- RLX 99.79
- PTGX 125.73
- 52 Week Low
- RLX $1.50
- PTGX $23.89
- 52 Week High
- RLX $2.37
- PTGX $48.89
- Technical
- Relative Strength Index (RSI)
- RLX 72.82
- PTGX 39.62
- Support Level
- RLX $2.13
- PTGX $35.03
- Resistance Level
- RLX $2.23
- PTGX $40.07
- Average True Range (ATR)
- RLX 0.09
- PTGX 1.56
- MACD
- RLX -0.00
- PTGX -0.04
- Stochastic Oscillator
- RLX 70.77
- PTGX 34.89
About RLX RLX Technology Inc. each representing the right to receive one (1) ordinary share
RLX Technology Inc is engaged in the manufacturing of e-vapor products for adult smokers. It has an integrated offline distribution and "Branded store plus" retail model tailored to China's e-vapor market.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.